Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

• Published in: Thrombosis journal 2018-11, Vol.16 (1), p.28-8, Article 28
• Main Authors: Sennesael, Anne-Laure, Larock, Anne-Sophie, Douxfils, Jonathan, Elens, Laure, Stillemans, Gabriel, Wiesen, Martin, Taubert, Max, Dogné, Jean-Michel, Spinewine, Anne, Mullier, François
• Format: Article
• Language: English
• Subjects: Anticoagulants; Bleeding; Cardiac arrhythmia; Direct oral anticoagulants; Drug monitoring; GLP-1 receptor agonists; Glycoproteins; Laboratories; Patient safety; Patients; Pharmacogenomics; Plasma; Risk factors; Rivaroxaban; Studies; Teaching hospitals; Thrombosis
• ISSN: 1477-9560; 1477-9560
• DOI: 10.1186/s12959-018-0183-3

Serious bleeding events have been frequently described in patients taking direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma concentrations were shown to correlate with bleeding outcomes. This study aimed to describe rivaroxaban plasma levels in patients admitted to the emergency department (ED) for bleeding events. For each patient, risk factors for experiencing bleeding events were also investigated. This analysis was part of an observational study conducted in the ED of two teaching hospitals. Plasma samples from 10 rivaroxaban-treated patients admitted for bleeding events were collected. Rivaroxaban plasma concentrations were determined by calibrated chromogenic anti-Xa assay. The measured rivaroxaban levels were then extrapolated at trough using a published population pharmacokinetic (PopPK) model, and compared to on-therapy ranges observed in large clinical trials. For each patient, clinical, medication and genotype data were collected. Rivaroxaban measurements varied from 5 to 358 ng/ml, with a post-intake delay ranging from 9 to 38 h. At trough, estimated plasma concentrations were between 12 and 251 ng/ml (median value 94 ng/ml). Four patients had higher-than-expected rivaroxaban levels. Inadequate dose regimen, excessive alcohol consumption and lack of treatment reassessment were observed in several patients. Half of patients were taking ≥1 drug with potential pharmacokinetics interactions (e.g. amiodarone, diltiazem), while half of patients were taking ≥1 drug increasing the risk of bleeding. All 3 patients with available genotyping data and higher-than-expected rivaroxaban levels were heterozygous or homozygous mutated for the 1236C > T, 2677G > T, 3435 C > T and rs4148738 single nucleotide polymorphisms (SNP). Rivaroxaban patients admitted to the ED for bleeding events showed highly variable plasma concentrations. This analysis underlines the usefulness of rapid DOAC measurement and the value of PopPK models to estimate concentrations at trough in a context where the post-intake delay is unmanageable. Close patient follow-up, including renal function assessment and drug interactions review, is essential for bleeding risk minimization.